A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes

Haematologica

Volumn 98, Issue 9, 2013, Pages 1375-1382

  Morris, Claudia R ^a   Kuypers, Frans A ^b   Lavrisha, Lisa ^c   Ansari, Michael ^c   Sweeters, Nancy ^c   Stewart, Melinee ^c   Gildengorin, Ginny ^b   Neumayr, Lynne ^c   Vichinsky, Elliott P ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^c CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; HYDROMORPHONE; KETOROLAC; MORPHINE SULFATE; PETHIDINE; PLACEBO;

ADOLESCENT; ARTICLE; BLOOD VESSEL OCCLUSION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION; HUMAN; MALE; PAIN; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL ANEMIA; URTICARIA; VISUAL ANALOG SCALE;

ADOLESCENT; ANALGESICS, OPIOID; ANEMIA, SICKLE CELL; ARGININE; CHILD; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84883621394     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.086637     Document Type: Article

References (50)

1. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997; 337(11):762-9.
2. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303(13):1288-94.
3. Yusuf HR, Atrash HK, Grosse SD, Parker CS, Grant AM. Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999-2007. Am J Prev Med. 2011;38(4 Suppl):S536-41.
4. Lanzkron S, Carroll CP, Haywood C Jr. The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. Am J Hematol. 2010;85(10):797-9.
5. Bundy DG, Strouse JJ, Casella JF, Miller MR. Urgency of emergency department visits by children with sickle cell disease: a comparison of 3 chronic conditions. Acad Pediatr. 2011;11(4):333-41.
6. Frei-Jones MJ, Baxter AL, Rogers ZR, Buchanan GR. Vaso-occlusive episodes in older children with sickle cell disease: emergency department management and pain assessment. J Pediatr. 2008;152(2):281-5.
7. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329 (27):2002-12.
8. Kaul DK, Liu XD, Fabry ME, Nagel RL. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol. 2000;278(6): H1799-806.
9. Aslan M, Ryan T, Adler B, Townes T, Parks D, Thompson J, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci. 2001;98(26):15215-20.
10. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med. 2008;44(8): 1506-28.
11. Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program. 2008;2008:177-85.
12. Reiter C, Wang X, Tanus-Santos J, Hogg N, Cannon R, Schechter A, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nat Med. 2002;8(12):1383-9.
13. Aslan M, Freeman BA. Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease--mechanisms and consequences. Cell Mol Biol (Noisy-le-grand). 2004;50(1):95-105.
14. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, VS, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA. 2005;294(1):81-90.
15. Enwonwu CO. Increased metabolic demand for arginine in sickle cell anaemia. Med Sci Res. 1989;17:997-8.
16. Morris CR, Kuypers FA, Larkin S, Vichinsky E, Styles L. Patterns of arginine and nitric oxide in sickle cell disease patients with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol. 2000; 22(6):515-20.
17. Waugh W, Daeschner C, Files B, Gordon D. Evidence that L-arginine is a key amino acid in sickle cell anemia-a preliminary report. Nutritional Res. 1999;19:501-18.
18. Lopez B, Kreshak A, Morris CR, Davis-Moon L, Ballas S, Ma X. L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol. 2003;120(3): 532-4.
19. Schnog JB, Jager EH, van der Dijs FP, Duits AJ, Moshage H, Muskiet FD, et al. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann Hematol. 2004;83:371-5.
20. Morris CR, Kuypers FA, Larkin S, Sweeter N, Simon J, Vichinsky EP, et al. Arginine therapy: A novel strategy to increase nitric oxide production in sickle cell disease. Brit J Haematol. 2000;111(12):498-500.
21. Morris CR, Barreda F, Leibovich SA, Rutherford M, Saulys A, Stewart M, et al. Quality improvement goals for sickle cell disease pain management in an urban pediatric emergency department: we can do better! 54th American Society of Hematology Annual Meeting, Atlanta, GA, December 2012. abstract 2101.
22. Morris CR, Morris SM Jr, Hagar W, van Warmerdam J, Claster S, Kepka-Lenhart K, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003;168(1):63-9.
23. Morris CR, Gladwin MT, Kato G. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med 2008;8 (7):81-90.
24. Romero J, Suzuka S, Nagel R, Fabry M. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood. 2002;99 (4):1103-8.
25. Dasgupta T, Hebbel RP, Kaul DK. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med. 2006;41(12):1771-80.
26. Kaul DK, Zhang X, Dasgupta T, Fabry ME. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodila tors, hemolysis, and oxidative stress. Am J Physiol Heart Circ Physiol. 2008;295(1): H39-47.
27. Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood. 2007;109(7):3088-98.
28. Little JA, Hauser KP, Martyr SE, Harris A, Maric I, Morris CR, et al. Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol. 2009;82(4):315-21.
29. Archer DR, Stiles JK, Newman GW, Quarshie A, Hsu LL, Sayavongsa P, et al. Creactive protein and interleukin-6 are decreased in transgenic sickle cell mice fed a high protein diet. J Nutr. 2008;138(6): 1148-52.
30. Gladwin MT, Barst RJ, Castro OL, Gordeuk VR, Hillery CA, Kato GJ, et al. Pulmonary hypertension and NO in sickle cell. Blood 2010;116(5):852-4.
31. Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010;116(5):687-92.
32. Sher GD, Olivieri NG. Rapid healing of leg ulcers during arginine butyrate therapy in patients with sickle cell disease and thalassemia. Blood. 1994;84(7):2378-80.
33. Morris CR, Vichinsky EP, van Warmerdam J, Machado L, Kepka-Lenhart D, Morris SM, Jr., et al. Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol. 2003;25(8):629-34.
34. th Convension of the National Sickle Cell Disease Program and the Sickle Cell Disease Association of America; 2007; Washington, DC; 2007. abstract no. 114.
35. Maxwell AJ, Cooke JP. Cardiovascular effects of L-arginine. Curr Opin Nephrol Hypertens. 1998;7(1):63-70.
36. Tang WH, Wang Z, Cho L, Brennan DM, Hazen SL. Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol. 2009;53(22):2061-7.
37. Sourij H, Meinitzer A, Pilz S, Grammer TB, Winkelmann BR, Boehm BO, et al. Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography. Atherosclerosis. 2011;218(1):220-5.
38. Omodeo-Sale F, Cortelezzi L, Vommaro Z, Scaccabarozzi D, Dondorp AM. Dysregulation of L-arginine metabolism and bioavailability associated to free plasma heme. Am J Physiol Cell Physiol. 2010;299(1):C148-54.
39. Morris CR, Teehankee C, Kato G, Gardner J, McGlothlin D, Malloy M, et al. Decreased arginine bioavailability contributes to the pathogenesis of pulmonary artery hypertension. American College of Cardiology Annual Meeting; 2005 March 6-9; Orlando, Florida; 2005.
40. Schnog JB, Teerlink T, van der Dijs FP, Duits AJ, Muskiet FA. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann Hematol. 2005;84(5):282-6.
41. Landburg PP, Teerlink T, Muskiet FA, Duits AJ, Schnog JJ. Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisis. Am J Hematol. 2008;83(7):577-9.
42. Kato GJ, Wang Z, Machado RF, Blackwelder WC, Taylor JG, Hazen SL. Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. Br J Haematol. 2009;145(4):506-13.
43. Vallance P. The asymmetrical dimethylarginine/ dimethylarginine dimethylaminohydrolase pathway in the regulation of nitric oxide generation. Clin Sci. 2001;100(2):159-60.
44. Hebbel RP. Auto-oxidation and a membrane-associated 'Fenton reagent': a possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol. 1985;14(1):129-40.
45. Morris CR, Suh JH, Hagar W, Larkin S, Bland DA, Steinberg MH, et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood. 2008;140:104-12.
46. Gornik HL, Creager MA. Arginine and endothelial and vascular health. J Nutr. 2004;134(10 Suppl):2880S-7S; discussion 95S.
47. Gladwin MT, Kato GJ, Weiner D, Onyekwere OC, Dampier C, Hsu L, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA. 2011;305 (9):893-902.
48. Berka V, Yeh HC, Gao D, Kiran F, Tsai AL. Redox function of tetrahydrobiopterin and effect of L-arginine on oxygen binding in endothelial nitric oxide synthase. Biochemistry. 2004;43(41):13137-48.
49. Wood KC, Hebbel RP, Lefer DJ, Granger DN. Critical role of endothelial cell-derived nitric oxide synthase in sickle cell diseaseinduced microvascular dysfunction. Free Radic Biol Med. 2006;40(8):1443-53.
50. Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood. 2011;118(4):855-64.